Insurance Specialist

Tandem Mobi automated insulin delivery system now available in twelve international markets. Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery system for people living with diabetes,[1] is now available in 12 countries outside the United States. The company is now taking orders and shipping to eligible customers in Belgium, the Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdom. Tandem Mobi, the world's smallest, durable insulin delivery system, now shipping in multiple international markets. Tandem Mobi is powered by Control-IQ+ technology, the predictive algorithm that automates insulin delivery. The system uses a Dexcom G7 continuous glucose monitoring system to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery every 5 minutes to help reduce high and low blood sugar. Tandem Mobi also offers multiple wear options, mobile app control through a compatible, personal iPhone,[*] and a 200-unit cartridge. Control-IQ+ technology has been evaluated in studies of people with type 1 diabetes, type 1 diabetes during pregnancy, and type 2 diabetes, including studies published by the and the, with results showing immediate and sustained glycemic improvements, including more time in range and improved sleep. J NextS SaveEsc Close Scroll

Abbott's Libre established as the "most connected CGM in the world" 10th September 2026 Abbott today announced the integration of its FreeStyle Libre 3 Plus sensor with Insulet's Omnipod(R) 5 Automated Insulin Delivery (AID) System in the UK, further expanding connected care options for people living with Type 1 diabetes who use a Libre sensor. The full UK availability of this latest integration builds on Abbott's FreeStyle Libre 3 Plus sensor and Tandem Diabetes Care's t:slim X2 insulin pump integration, which became available this summer. Based on the number of pump users having the ability to connect with Libre technology globally these latest partnerships establish Libre as the most connected continuous glucose monitoring (CGM) technology in the world*, providing users with access to more pump options globally than any other CGM. Today, in the UK, Abbott's connected diabetes management solutions are compatible with the following automated insulin delivery systems, or insulin pumps: * Insulet's Omnipod(R) 5 with both the FreeStyle Libre 3 Plus and the FreeStyle Libre 2 Plus sensors * Tandem Diabetes Care's t:slim X2 insulin pump with the FreeStyle Libre 3 Plus sensor * mylife Diabetes Care's YpsoPump insulin pump with the FreeStyle Libre 3 Plus sensor * MiniMed(TM) 780G system with the Instinct sensor, made exclusively by Abbott and distributed by Medtronic Hybrid closed loop systems like these combine a CGM with an insulin pump to automatically adjust insulin delivery based on glucose readings. They help people spend less time managing their condition and more time focusing on the things that matter to them. Libre technology provides real-time, personalised insights to help people understand how food, activity and medications affect their bodies. The latest Libre innovation is the world's first dual glucose-ketone sensor, which monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis, a serious diabetes-related complication. Graeme Scott, 58, from Angus, who lives with type 1 diabetes said: "My life has changed immensely for the better since starting on a hybrid closed loop system. Having my sensor and pump working together gives me greater confidence and flexibility day-to-day, helping reduce the burden of managing diabetes. The technology means I spend less time thinking about my glucose levels and more time focusing on the things I enjoy. I'm running my own life instead of letting diabetes run it for me." Julia Hammac, General Manager for Abbott's diabetes care business in the UK, said: "For people living with type 1 diabetes, having access to technologies that work seamlessly together can make a meaningful difference to day-to-day diabetes management. By expanding our hybrid closed loop partnerships, we're giving people more choice in how they manage their condition and helping make advanced diabetes technologies more accessible through connected care solutions." Hilary Nathan, Director of Policy and Communications at Breakthrough T1D said: "For many people living with type 1 diabetes, technology is part of everyday life. Having choice really matters. Everyone's experience of diabetes is different, and what works brilliantly for one person may not be right for another. We welcome developments that give people more options and greater flexibility in how they manage their condition, allowing them to choose technology that fits their individual needs, preferences and lives. Ultimately, we want to see a technology landscape shaped around the people who use it, with the freedom to choose the tools that work best for them and today's announcement helps us take one step further towards that." *Data on File, Abbott Diabetes Care

Tandem Diabetes Care is positioned for growth through expanding product choices and a pay-as-you-go reimbursement model that lowers upfront costs whilst supporting higher recurring supply revenue. The company submitted a 510(k) for its Mobi tubeless pump targeting a 2026 launch and received FDA approval to begin a pivotal study for its fully closed-loop AIDANET programme. In the second quarter of 2026, pharmacy sales reached 10% of US sales, up from 6% in the first quarter, with formulary coverage at approximately 45%. Tandem reaffirmed its 2026 sales guidance of $1.065-$1.085 billion. The stock has risen 59% over the past year, against a 5.4% industry decline. The company holds a Zacks Rank #3 (Hold) with a market capitalisation of $1.05 billion.